Eosinophilic Otitis Media Treated with Anti-IgE Monoclonal Antibodies and A Bone Conduction Implant
Author(s) -
Young Eun Han,
Yong Seok Kang,
Younhoon Cho,
Moo Kyun Park
Publication year - 2018
Publication title -
the journal of international advanced otology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.518
H-Index - 13
eISSN - 2148-3817
pISSN - 1308-7649
DOI - 10.5152/iao.2018.4517
Subject(s) - medicine , otitis , eosinophilic , bone conduction , omalizumab , hearing loss , middle ear , dermatology , immunoglobulin e , immunology , surgery , antibody , audiology , pathology
Eosinophilic otitis media (EOM) are intractable otitis media characterized by highly viscous secretions containing eosinophils in the middle ear. They are resistant to conventional medication and surgery. This condition occurs primarily in patients with bronchial asthma or allergic rhinitis and is often complicated by rhinosinusitis. Systemic and topical steroid therapies are effective treatments. However, long-term steroid therapy is often limited by a high risk of serious adverse effects. The use of topical steroids and otorrhea are bothersome when wearing hearing aids. Here, we report a case of intractable otitis media due to EOM. Otorrhea was controlled with topical steroids. Bone conduction hearing was stable for an extended period with anti-IgE monoclonal antibodies (omalizumab). An implantable bone conduction hearing aid was used for rehabilitation of conductive hearing loss.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom